Soliton to Report First Quarter 2021 Financial Results on May 13, 2021

Rhea-AI Summary

Soliton, Inc. (Nasdaq: SOLY), a medical device firm, will release its first quarter 2021 financial results on May 13, 2021, before market open. A conference call is scheduled for the same day at 4:30 p.m. ET to discuss these results. Soliton's key product, RESONIC™, utilizes acoustic shockwaves for non-invasive treatment of cellulite and tattoo removal. The company is based in Houston, Texas, and the technology could improve treatment profitability while reducing patient costs. Investors can access the call via the company's website.

Positive

• Scheduled release of first quarter 2021 financial results on May 13, 2021.
• RESONIC™ is FDA cleared for tattoo removal and cellulite treatment, enhancing market opportunities.
• Potential to lower patient costs and increase practitioner profitability compared to current methods.

Negative

• None.

HOUSTON, May 4, 2021 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology, today announced that the Company is scheduled to release its first quarter 2021 financial results on Thursday, May 13, 2021, before market open.

Soliton will host a conference call on Thursday, May 13, 2021, at 4:30 p.m. ET to discuss the results. The dial-in numbers for the conference call are (833) 423-0479 for domestic callers and (918) 922-2373 for international callers. The conference ID number is 4989465.

A live audio webcast of the call will be available on the Investor Relations page of the Soliton, Inc. website, https://www.soliton.com/. A replay of the webcast will be archived on Soliton's website for 30 days following the completion of the call.

In addition, a telephonic replay of the call will be available until May 20, 2021. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the replay conference ID number 4989465.

------------------------
Join our more than 200K subscribers here to follow the Company: https://soly-investors.com
------------------------

About Soliton, Inc.

Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of MD Anderson Cancer Center. The Company's first FDA cleared commercial product, RESONIC™, will use rapid pulses of acoustic shockwaves for the treatment of cellulite and as an accessory to lasers for the removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in bringing RESONIC to the market. The Company believes this "Soliton" method has the potential to lower tattoo removal costs for patients, while increasing profitability to practitioners, compared to current laser removal methods. The Company also believes the technology will provide the first non-invasive acoustic technology to target the underlying causes of dimples and ridges in cellulite. Soliton is investigating potential additional capabilities of the RAP technology. The device is currently cleared in the United States only for use in tattoo removal and cellulite.

For more information about the Company, please visit: http://www.soliton.com

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which statements involve risks and uncertainties. These statements relate to future events, future expectations, plans and prospects. Although Soliton believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, actual results or outcomes may prove to be materially different from the expectations expressed or implied by such forward-looking statements. Soliton has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' "would," ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed in our filings with the Securities and Exchange Commission ("SEC"), including under the heading " Risk Factors" in our most recently filed Form 10-K filed with the SEC and as updated in our Form 10-Q filings and in our other filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. Soliton undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

View original content to download multimedia:http://www.prnewswire.com/news-releases/soliton-to-report-first-quarter-2021-financial-results-on-may-13-2021-301282443.html

SOURCE Soliton, Inc.

FAQ

When will Soliton release its first quarter 2021 financial results?

Soliton will release its first quarter 2021 financial results on May 13, 2021, before market open.

What can investors expect during Soliton's conference call on May 13, 2021?

Investors can expect a discussion of the first quarter 2021 financial results during the conference call scheduled for 4:30 p.m. ET.

What is the conference ID for Soliton's May 13, 2021, conference call?

The conference ID number for Soliton's conference call is 4989465.

What are the applications of Soliton's FDA cleared product RESONIC™?

RESONIC™ is cleared for the treatment of cellulite and as an accessory for tattoo removal.

How can I access the live audio webcast of Soliton's conference call?

The live audio webcast can be accessed on the Investor Relations page of Soliton's website.